newsfilter
← Latest News
ClinicalTrials.gov·

A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer - NCT05275673

Investigator-Assessed Overall Response Rate (ORR) per RECIST v1.1., Number of Participants With Adverse Events (AEs), Serious AEs, Deaths, and Discontinuations Due to AEs, Duration of Response (DOR), (and 4 more...)